Organogenesis Holdings Inc [ORGO] stock is trading at $4.26, up 13.60%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ORGO shares have gain 10.08% over the last week, with a monthly amount drifted -18.86%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Organogenesis Holdings Inc [NASDAQ: ORGO] stock has seen the most recent analyst activity on June 28, 2024, when Lake Street initiated its Buy rating and assigned the stock a price target of $5. Previously, Cantor Fitzgerald started tracking the stock with Overweight rating on February 07, 2024, and set its price target to $5. On June 15, 2023, Morgan Stanley initiated with a Equal-Weight rating and assigned a price target of $5 on the stock. BTIG Research upgraded its rating to a Buy but stick to its price target of $10 on May 24, 2023. BTIG Research downgraded its rating to a Neutral. Oppenheimer downgraded its rating to Perform for this stock on August 10, 2022. In a note dated January 10, 2020, SVB Leerink initiated an Outperform rating and provided a target price of $9 on this stock.
Organogenesis Holdings Inc [ORGO] stock has fluctuated between $2.16 and $6.71 over the past year. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Organogenesis Holdings Inc [NASDAQ: ORGO] shares were valued at $4.26 at the most recent close of the market. An investor can expect a potential return of 40.85% based on the average ORGO price forecast.
Analyzing the ORGO fundamentals
Organogenesis Holdings Inc [NASDAQ:ORGO] reported sales of 482.04M for the trailing twelve months, which represents a growth of 27.10%. Gross Profit Margin for this corporation currently stands at 0.74% with Operating Profit Margin at -0.0%, Pretax Profit Margin comes in at -0.01%, and Net Profit Margin reading is 0.0%. To continue investigating profitability, this company’s Return on Assets is posted at 0.0, Equity is 0.0 and Total Capital is -0.0. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.16.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.79 points at the first support level, and at 3.33 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.50, and for the 2nd resistance point, it is at 4.75.
Ratios To Look Out For
For context, Organogenesis Holdings Inc’s Current Ratio is 3.69. Also, the Quick Ratio is 3.35, while the Cash Ratio stands at 1.75. Considering the valuation of this stock, the price to sales ratio is 1.12, the price to book ratio is 2.04 and price to earnings (TTM) ratio is 760.71.
Transactions by insiders
Recent insider trading involved Driscoll Michael Joseph, Director, that happened on Mar 04 ’25 when 25000.0 shares were purchased. Director, Driscoll Michael Joseph completed a deal on Mar 04 ’25 to sell 25000.0 shares. Meanwhile, President and CEO Gillheeney Gary S. sold 55615.0 shares on Dec 13 ’24.
